Vir Biotech Catapults On Its $1.71 Billion Deal With Astellas - Investor's Business Daily
AI Summary1 min read
TL;DR
Vir Biotechnology's stock surges after announcing a $1.71 billion collaboration with Astellas to develop VIR-5500, a prostate cancer drug, including a $240 million upfront payment.
Tags
Vir BiotechnologyAstellasprostate cancerbiotech dealVIR-5500
- Vir Biotech Catapults On Its $1.71 Billion Deal With Astellas Investor's Business Daily
- Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer PR Newswire
- Astellas pays $240M cash for Vir’s prostate cancer drug Endpoints News
- This Small-Cap Biotech Stock Is Soaring 29%. There’s Excitement Over Its Prostate Cancer Drug. Barron's
- ‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific Fierce Biotech